

—Inflation Reduction Act Research Series—

Entresto: Medicare Enrollee Use and Spending

This Fact Sheet provides information on **Entresto**, one of the 10 drugs selected for the first cycle of Medicare drug price negotiations. Entresto (active ingredient sacubitrilat/valsartan) is a small molecule drug used to treat heart failure. Medicare enrollees may have a high risk of heart failure due to age and other comorbidities present among this population. Existing data shows about 15 percent of Medicare enrollees have been diagnosed with heart failure.

- Between 2018 and 2022, average annual total Part D spending per enrollee taking Entresto (i.e., the total amount, including Medicare, plan, and enrollee payments, spent on Entresto per person) increased by 51 percent (from \$3,162 to \$4,780).
- From 2018 through 2022, the average annual out-of-pocket spending per enrollee increased by 13 percent (from \$315 to \$357).

Table 1 presents data on utilization and spending for Entresto among Part D enrollees. About 521,000 Part D enrollees filled prescriptions for Entresto in 2022. Relative to the total Part D population, a greater share of Entresto users were men (62 percent vs. 44 percent) and Black non-Latinos (18 percent versus 11 percent).

Table 1. Medicare Part D Use and Spending on Entresto, Calendar Year (CY) 2022

	Total Enrollees	LIS Enrollees ^a	Non-LIS Enrollees
Number of Part D Enrollees	53,063,000	14,957,000	38,106,000
Number of Enrollees Taking Entresto	521,000	203,000	318,000
Share of Part D Enrollees Taking Entresto	1%	1%	1%
Total Spending on Entresto			
Total Spending	\$2,489,720,000	\$1,023,359,000	\$1,466,361,000
Average per Enrollee taking Entresto	\$4,780	\$5,035	\$4,616
Enrollee Out-of-Pocket Spending on Entresto			
Total OOP Spending	\$185,802,000	\$5,176,000	\$180,625,000
Average OOP per Enrollee taking Entresto	\$357	\$25	\$569

Notes: ^aFor eligible Part D enrollees who meet income and asset requirements, the Low-Income Subsidy (LIS), also known as Extra Help, provides assistance with premiums, deductibles, and co-payments for covered Part D drugs.

The Inflation Reduction Act was signed into law by President Biden in August 2022. Please see [here](#) for more information on how the law is reducing drug costs for Medicare beneficiaries.

Please see [here](#) for more information on Entresto and the other drugs selected for the first cycle of Medicare drug price negotiation, cautions and limitations in interpretation and use of these estimates, and relevant citations.